A study reports that a treat-to-target strategy for early rheumatoid arthritis (RA) is linked to better long-term outcomes. Researchers find that patients who achieve sustained remission by two years have higher remission rates and improved physical function at 10 years, with radiographic changes remaining relatively modest over that decade.

The findings come from follow-up of a clinical trial described in medical research outlets. Both reports emphasize that early, closely managed treatment—using predefined targets and adjustments—can translate into durable benefits rather than short-term control. While the studies focus on different aspects of long-term results (such as sustained remission versus overall remission rates and imaging progression), the overall message across sources is consistent: stringent treat-to-target management in early RA is associated with favorable outcomes through 10-year follow-up.